Centauri Therapeutics Limited

Centauri Therapeutics Limited, based in the UK, focuses on developing innovative immunotherapy solutions to combat infectious diseases and oncology, utilizing its proprietary Alphamer® technology. Centauri Therapeutics Limited specializes in immunotherapy solutions, leveraging its proprietary Alphamer® platform to redirect existing antibodies against severe infections. Founded in 2014 in London, UK, the company has undergone various strategic developments, focusing primarily on European markets. This platform redirects naturally existing antibodies to combat life-threatening infections, particularly focusing on Gram-negative bacterial infections.

The Alphamer® technology is clinically validated, underscoring its effectiveness in treating vulnerable patient populations. The primary end users are healthcare providers and clinical institutions seeking advanced therapeutic options. While the initial focus is on European markets, there are plans for potential expansion into North America and other regions. Centauri Therapeutics has engaged in various funding activities to support its research and development initiatives, receiving significant investments, including a EUR 24.

00 mn Series A investment round. Revenue generation may stem from collaborations, grants, and potential licensing agreements for its proprietary technology. In July 2025, Centauri Therapeutics Limited raised GBP 3. 8 million in venture funding from returning investor CARB-X.

The company's flagship products are positioned for direct marketing to healthcare providers, potentially involving sales agreements or collaborations with pharmaceutical companies. In February 2026, Centauri Therapeutics Limited raised GBP 30 million in series A funding from new investor AMR Action Fund. The company will use the February 2026 funding to support its completion of Phase I clinical studies for its antimicrobial treatments, including its lead candidate CTX-187.